TAMMY MCCULLOUGH: Open Payments
NPI 1316974082 · BROWNWOOD, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$459 in 26 payments from 12 companies in 2025. Trend: 2023 $316 · 2024 $284 · 2025 $459
Food & beverage: $459
| Company | Payments | Amount |
|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. | 5 | $88 |
| ABBVIE INC. | 3 | $70 |
| Novo Nordisk Inc | 4 | $60 |
| Alnylam Pharmaceuticals Inc. | 2 | $42 |
| PFIZER INC. | 2 | $37 |
| Bayer Healthcare Pharmaceuticals Inc. | 2 | $34 |
| AstraZeneca Pharmaceuticals LP | 2 | $32 |
| E.R. Squibb & Sons, L.L.C. | 1 | $25 |
| Dexcom, Inc. | 1 | $21 |
| Phathom Pharmaceuticals, Inc. | 2 | $17 |
Products named: JARDIANCE, VRAYLAR, Ozempic, ELIQUIS, GIVLAARI, Kerendia, FARXIGA, OFEV.
Industry payments across TX — which companies pay providers there.
